Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Arrowhead Pharma (ARWR) ENaC News 'Not Thesis Changing', RBC Says; PT Lowered to $83
July 2, 2021 12:16 PM EDTRBC Capital analyst Luca Issi lowered the price target on Arrowhead Pharma (NASDAQ: ARWR) to $83.00 (from $90.00) while maintaining a Outperform rating following news the company is voluntarily pausing the Phase I/II trial for ENaC due to local lung inflammation seen in rats.... More
Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback
July 2, 2021 10:02 AM EDTCiti analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with... More
Arrowhead (ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
July 2, 2021 7:45 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
... More